Monthly Archives: March 2026

By Eric Green, CEO of Trace Neuroscience, as part of the From The Trenches feature of LifeSciVC Few neurodegenerative diseases have clearer genetic causation than Huntington’s disease (HD). And yet for decades, translating that genetic clarity into desperately needed effective

An IPO remains one of the most sought-after brass rings on the startup carousel, viewed as an important milestone on a biotech’s journey and a major financing event for powering up an emerging company.  It’s also one of the most

By Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC Of the recurring themes that tend to circulate in the drug development discourse,  China is a uniquely fascinating and polarizing subject.

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC As biotech companies tackle the escalating time and cost of clinical trials, the decision to conduct early-stage, proof-of-concept studies outside the U.S. is